jRCT1080224979CompletedPhase 3
A confirmatory study of CL2020 in patients with ST-elevation myocardial infarction
Life Science Institute Inc.1 site83 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 83
- Locations
- 1
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Intervention Model
- A Multicenter, Randomized, Double-blind, Parallel-group Study
- Primary Purpose
- Treatment Purpose
Eligibility Criteria
- Ages
- 20age old over to 80age old under (—)
- Sex
- All
Inclusion Criteria
- •Patients diagnosed ST-elevation myocardial infarction
- •Patients with cardiac dysfunction in spite of successful reperfusion by PCI
Exclusion Criteria
- •Patients with any existing or previous malignant tumor
- •Pregnant or nursing women, or women of child-bearing potential
Outcomes
Primary Outcomes
-
efficacy Left ventricular ejection fraction after infusion of CL2020
Secondary Outcomes
- left ventricular end-systolic volume
- left ventricular end-diastolic volume
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A clinical study of CL2020 in patients with spinal cord injuryspinal cord injuryJPRN-jRCT1080224764ife Science Institute Inc.10
Recruiting
Not Applicable
A Phase III Study of CLS2901C in Patients with Osteoarthritis of the KneejRCT2033230587CellSeed Inc.96
Not yet recruiting
Phase 2
Clinical trial of NRL/DST/19-20 in patients suffering from primary insomnia, stress and anxietyCTRI/2020/06/025697etsurf Communications Pvt Ltd
Completed
Not Applicable
Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection (Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection)jRCT2043210005Life Science Institute, Inc.43
Completed
Phase 1
Clinical study of CL2020 in patients with acute respiratory distress syndrome associated with SARS-CoV-2 infectioJPRN-jRCT2043210005Fukushima Tatsunobu43